The cardiac work-loop technique: An in vitro model for identifying and profiling drug-induced changes in inotropy using rat papillary muscles

Sophie Fletcher1,2, Helen Maddock1,2*, Rob S. James3, Rob Wallis2 & Mayel Gharanei1,2

The cardiac work-loop technique closely mimics the intrinsic in vivo movement and characteristics of cardiac muscle function. In this study, six known inotropes were profiled using the work-loop technique to evaluate the potential of this method to predict inotropy. Papillary muscles from male Sprague-Dawley rats were mounted onto an organ bath perfused with Krebs-Henseleit buffer. Following optimisation, work-loop contractions were performed that included an initial stabilisation period followed by vehicle control or drug administration. Six known inotropes were tested: digoxin, dobutamine, isoprenaline, flecainide, verapamil and atenolol. Muscle performance was evaluated by calculating power output during work-loop contraction. Digoxin, dobutamine and isoprenaline caused a significant increase in power output of muscles when compared to vehicle control. Flecainide, verapamil and atenolol significantly reduced power output of muscles. These changes in power output were reflected in alterations in work loop shapes. This is the first study in which changes in work-loop shape detailing for example the activation, shortening or passive re-lengthening have been linked to the mechanism of action of a compound. This study has demonstrated that the work-loop technique can provide an important novel method with which to assess detailed mechanisms of drug-induced effects on cardiac muscle contractility.

The primary function of the heart is as a mechanical pump; undergoing two main phases during each cardiac cycle: contraction (systole) and relaxation (diastole). A change in contractility, as a result of pharmacological interventions (inotropy) or a pathophysiological condition, would therefore impact on the hearts intrinsic ability to act as a mechanical pump. Hence, it is important to have a reliable index of contractility both in vivo and in vitro.

The most reliable way to measure changes in contractility in vivo is by measuring changes in left ventricular pressure and volume, as first suggested by Suga and Sagawa1. The relationship between pressure and volume has since become a widely accepted index of cardiac contractility2. Because of the general applicability of this concept to hearts of all species, pressure-volume analysis has become the favoured practice for assessing contractility in pre-clinical studies of all mammals including mice, dogs and non-human primates. Telemetry studies involving conscious animals are often considered to be the gold standard for pre-clinical contractility assessment; often by measuring changes in pressure or volume or other measures such as LVDP/dt max3. However, the use of telemetry is expensive, has a relatively slow throughput, and requires the use of live animals. Hence, such measurements are often carried out late in the development of new pharmacological compounds.

Although the pressure-volume relationship is the most direct and reliable way to measure contractility in vivo, in a clinical setting the pressure-volume relationship is rarely measured directly to assess changes in contraction and heart function. The use of conductance catheters to measure this relationship is highly reliable, however, it is invasive, complex, expensive and technically demanding2. One technique routinely used to identify changes in cardiac performance and contractility in a clinical setting is the method of echocardiography; it is currently recommended by National Institute for Health and Care Excellence in the diagnosis and monitoring of acute and chronic heart failure45. Echocardiograms are commonly used to assess the structure and function of the heart. Function is quantified using estimations of cardiac output, ejection fraction and diastolic function. The biggest

1Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, United Kingdom. 2InoCardia Ltd, Technocentre, Puma Way, Coventry, CV1 2TT, UK. *email: h.maddock@coventry.ac.uk
advantages of echocardiography are that it is non-invasive and relatively inexpensive meaning it can be used routinely. However, haemodynamic parameters such as cardiac output and ejection fraction are not measured directly but estimated based on other measurements\(^6\), meaning there is a higher degree of error compared to more direct measurements.

It is important to have a reliable in vitro measure of cardiac contractility which can be used in a translatable manner in order to predict changes in vivo and to help us better understand complex pathophysiological conditions. There are many in vitro techniques which can be used to assess contractility, ranging from whole heart to those using single cardiomyocytes. A well-established in vitro technique commonly used to assess changes in contractility is the Langendorff perfused heart model\(^6\). The Langendorff technique utilises the whole heart (routinely small mammals such as rats or mice) which is perfused in a retrograde manner under constant pressure. One of the main benefits of this technique is that there are no diffusion constraints as the vasculature of the heart is utilised in the perfusion of compounds it is also possible to acquire electrocardiogram traces during experiments\(^9\).

One of the main disadvantages is that there is a lack of afterload which does not reflect biomechanics in vivo.

Muscles isolated from the myocardium can also be utilised in vitro and are predominantly used in isometric contraction studies, during which the muscles are held at a constant length and stimulated to produce a twitch response\(^6\). However, in vivo cardiac muscle is rarely at constant length during contraction and relaxation, hence, isometric contraction studies do not fully replicate the dynamic cardiac muscle movement observed in vivo. Isometric contraction studies also overestimate the power output of a muscle as they do not account for the fact that muscles cannot be continuously maximally activated; time is required for relaxation, re-lengthening and activation\(^11\).

Another class of techniques currently used experimentally to assess contractility are cellular assays such as impedance- or sarcomere shortening-assays\(^6\). These techniques have the potential to be higher throughput than those mentioned previously. However, one main drawback of these methods is that generally the cardiomyocytes are unloaded which is not representative of in vivo conditions. Also, impedance is not a direct measure of contraction but merely a surrogate.

In isolated muscles or cells, it is not possible to measure changes in pressure and volume because the atria and ventricles are no longer intact. In the cardiac work-loop technique changes in force and length are measured instead. The technique incorporates a sinusoidal length change along with electrical stimulation that closely mimics the cardiac cycle in vivo and has the potential to be used pre-clinically to identify changes in contractility. It has been suggested that strain patterns that occur in vivo are almost sinusoidal in shape\(^19\), whilst the exact strain patterns are more complex in nature, a sinusoidal length change offers a good approximation of in vivo muscle mechanics\(^21\).

The work-loop technique has previously been utilised in studies of both skeletal\(^11,22,23\) and cardiac muscle\(^24,25\). Layland et al.\(^26\) have previously investigated the effect of 5µM isoprenaline and 100µM of phenylephrine on the power output of isolated rat ventricular trabecular muscles. This study successfully demonstrated that both isoprenaline and phenylephrine increased the power output of the trabecular muscles using the cardiac work-loop technique and hence were positive inotropes. However, the study was not performed at a physiologically relevant temperature (24 °C) and relatively high concentrations of both compounds were used.

Prior to the current study, extensive work has been carried out in our laboratory in order optimise the cardiac work-loop technique to identify drug-induced changes in contractility by testing six known inotropes. The power output of the muscles was measured and compared statistically to a suitable vehicle control. The shape of the work-loop during drug treatment was compared to that during stabilisation and any changes in the work-loop shape were linked to the mechanism of action of the compound. The aim of the study was to demonstrate that the cardiac work-loop using rat papillary muscles has the potential to be used as an in vitro technique to identify drug induced changes in contractility.

**Materials and Methods**

**Chemicals.** Isoprenaline hydrochloride, atenolol and verapamil hydrochloride were purchased from Abcam (Cambridge, UK). Dobutamine hydrochloride, digoxin and flecainide acetate were purchased from Tocris Bioscience (Oxford, UK). Stock solutions (1–10 mM) of all compounds were made and were stored at −20°C. Digoxin and dobutamine were dissolved in dimethyl sulfoxide (DMSO) to make the stock solution. The final concentration of DMSO during experimentation was less than 0.01%. Verapamil, atenolol, flecainide and isoprenaline were all dissolved in ultra-pure water to make the stock solution. All other reagents were purchased from either Sigma Aldrich (Dorset, UK) or Fisher Scientific (Loughborough, UK) unless stated otherwise.

**Animals.** Male Sprague-Dawley rats were used in all experiments; they were obtained from Charles River (Margate, UK) and housed at the University of Warwick. Experiments were conducted in accordance with the Guidelines on the Operation of Animals (Scientific Procedures Act 1986) and were approved by the Coventry University ethics committee.

**Papillary muscle dissection.** Muscle preparation was similar to that previously described\(^12\). Rats were sacrificed via cervical dislocation; the hearts were then carefully and rapidly excised and placed into ice-cold, oxygenated (100% O\(_2\)) Krebs Henseleit (KH) buffer. The KH buffer comprised of: NaCl (144 mM), Na Pyruvate (10 mM), HEPES [4-(2-hydroxyethyl)–1-piperazineethanesulfonic acid] (10 mM), KCl (6 mM), CaCl\(_2\)·2H\(_2\)O.
During all experiments, work-loop contractions were carried out using the following parameters: initial length of 90% Lmax, strain amplitude ± 4%, cycle frequency = 6 Hz, pulse width of stimulation = 1.0 ms and a current of 120 mA was used for all stimulations (parameters were established during preliminary optimisation experiments, data not shown).

At the end of the experiments, the wet muscle mass was measured to the nearest 0.00001 g using an electronic balance (Sartorius BP211D, Germany). Muscle mass, fibre length and the assumed muscle density of 1060 kg m⁻³ were used to calculate fibre cross-sectional area and the isometric muscle stress.

Analysis. Work-loop traces were produced by plotting the force against the length (or strain) of the muscle. Figure 2 depicts a typical cardiac work-loop and its three main phases. It also depicts how net work can be calculated based on the net area of the loop. In this study net power output was calculated which is proportional to the instantaneous force by the instantaneous velocity. The instantaneous power output values were then averaged to give average net power output value. The average net power output value was then adjusted to account for muscle mass. For each of the time courses, the power output during the vehicle- or drug- treatment was expressed as a percentage of the average power output during stabilisation.

All six drug treatments were compared to a time-matched vehicle control treatment. The data were expressed as mean ± SEM. Power output values were assessed for statistical differences, p < 0.05 was considered statistically significant. A repeated measure two-way analysis of variance (ANOVA) was performed, if the ANOVA was
Results

Muscle characteristics. The characteristics of the muscle preparations following length optimisation and before any drug or control treatment are shown in Table 1. All experimental groups were compared using a one-way ANOVA (analysis of variance) with post-hoc Bonferroni test. There were no significant differences (p > 0.05) between the experimental groups for the following characteristics: Lmax, active force, passive force, developed force, fibre CSA and stress (all at Lmax), muscle mass and net power output at the end of stabilisation.

Drug induced changes on muscle performance. For all six drug treatments, a time-course and a pair of representative work-loops have been presented in the figures below (Figs. 3, 4, 5, 6, 7, 8). The time-course

---

Table 1. Characteristics of papillary muscle preparations. Lmax, length at which maximum force was produced; CSA, cross-sectional area. Unless specified all values are for when the muscle is at length Lmax. Values are mean ± SD (n = 6–9).

|                          | KH Vehicle Control (n = 7) | 0.01% DMSO Vehicle Control (n = 7) | Digoxin (n = 6) | Dobutamine (n = 9) | Isoprenaline (n = 7) | Verapamil (n = 7) | Flecaïnide (n = 8) | Atenolol (n = 8) |
|--------------------------|---------------------------|------------------------------------|-----------------|-------------------|---------------------|------------------|-------------------|------------------|
| Lmax (mm)                | 2.10 ± 0.71               | 2.71 ± 0.72                         | 1.85 ± 0.57     | 2.19 ± 0.41       | 1.70 ± 0.62         | 2.18 ± 0.52       | 2.20 ± 0.87       | 2.45 ± 0.45       |
| Active Force (mN)        | 17.4 ± 4.5                | 23.2 ± 6.5                          | 17.3 ± 3.8      | 23.1 ± 7.4        | 19.9 ± 4.3          | 21.5 ± 8.3        | 24.4 ± 10.8       | 20.7 ± 7.5        |
| Passive Force (mN)       | 5.4 ± 1.4                 | 6.2 ± 2.1                           | 6.1 ± 1.5       | 7.5 ± 1.3         | 7.1 ± 1.4           | 5.8 ± 1.6         | 8.2 ± 1.3         | 5.8 ± 2.1         |
| Developed Force (mN)     | 11.9 ± 3.5                | 17.0 ± 5.3                          | 11.2 ± 3.1      | 15.6 ± 6.2        | 12.8 ± 3.1          | 15.7 ± 7.6        | 15.5 ± 10.1       | 14.8 ± 6.4        |
| Fibre CSA (m²)           | 3.2 × 10⁻⁷ ± 1.2 × 10⁻⁷   | 2.7 × 10⁻⁷ ± 1.0 × 10⁻⁷             | 4.3 × 10⁻⁷ ± 2.6 × 10⁻⁷ | 2.7 × 10⁻⁷ ± 1.1 × 10⁻⁷ | 2.5 × 10⁻⁷ ± 1.4 × 10⁻⁷ | 4.1 × 10⁻⁷ ± 1.2 × 10⁻⁷ | 2.7 × 10⁻⁷ ± 1.1 × 10⁻⁷ | 3.0 × 10⁻⁷ ± 1.4 × 10⁻⁷ |
| Isometric Stress (kN m⁻³) | 4.1 ± 16                  | 65 ± 10                             | 37 ± 23         | 60 ± 15           | 56 ± 21             | 41 ± 25           | 49 ± 19           | 48 ± 16           |
| Muscle Mass (µg)         | 677 ± 2.82                | 722 ± 304                           | 778 ± 397       | 636 ± 305         | 554 ± 452           | 866 ± 392         | 684 ± 481         | 873 ± 431         |
| Average net power (end of stabilisation) (W/kg⁻¹) (at 90% Lmax) | 9.9 ± 4.7 | 18.2 ± 3.5 | 10.1 ± 6.7 | 15.1 ± 4.0 | 14.8 ± 8.1 | 9.7 ± 4.4 | 16.4 ± 7.8 | 14.2 ± 4.8 |

Figure 2. Adapted from Gharanei et al. 2014 showing: (a) typical force, (b) length and (c–f) work-loop traces. The cardiac work-loop consists of three main phases which have been labelled in each diagram. (a) typical force trace of a cardiac work-loop. (b) typical sinusoidal length trace of a cardiac work-loop. (c) typical work-loop trace showing 3 main phases: (1) Activation of the muscle. (2) Shortening of the muscle (3) Passive re-lengthening of the muscle. (d) Phase 1 is highlighted- during this phase the muscle is simultaneously stimulated electrically and lengthened. The shaded area depicts the work required to lengthen the muscle from initial length to maximum length. (e) Phase 2 is highlighted- once the peak force has been reached the length of the muscle is shortened to below that of the original length. The force gradually decreases during this period. The area highlighted during this phase is the total work done during shortening. (f) Phase 3 is highlighted - during this phase the muscle is re-lengthened back to its starting length. The area highlighted is the work required to re-lengthen the muscle to initial length. The net work, which corresponds to the area within the loop can be calculated as: area 2 – (area 1 + area 3).
depicts the mean (±SEM) power output of the muscle preparations over 80 minutes. The effect of positive and negative inotropes on the power output of the muscle over time are demonstrated and how they compare to the time-matched vehicle treatment. For the representative work-loops a loop from the end of stabilisation (20 minutes) has been compared to a work-loop from the time point of maximal drug response (based on power output values).

**Positive inotropes.** As shown in Fig. 3a, digoxin (1 µM) caused a significant and sustained increase in the power output of the muscle. After 10 minutes of treatment, digoxin caused a significant (p = 0.033) increase in power output when compared to the time-matched vehicle control; a significant difference was maintained for the remainder of the experiment. The greatest increase in contractility was observed 30 minutes into the drug treatment with an increase in power output of 27% (±9%) compared to the vehicle control treatment (p = 0.001). Digoxin elicited its effect primarily during the second phase of the work-loop where it caused an increase in the force throughout muscle shortening, there was also an increase in the peak force when compared to the work-loop from stabilisation (Fig. 4b). An increase in the peak force was observed, however, this increase in force was not sustained throughout the whole of the second phase. During the third phase, the force during re-lengthening was lower compared to stabilisation which reduced the negative work during re-lengthening to initial length and hence net power output.

Dobutamine (1 µM) also caused a significant increase in the power output of the muscle (Fig. 4a). After 5 minutes of drug treatment, dobutamine caused a significant increase in the power output of the muscle (p = 0.005) when compared to time-matched controls. The maximal response was recorded 10 minutes into the drug treatment with an increase in power output of 20% (±6%) when compared to the vehicle control treatment. A significant increase in power output was sustained for the remainder of the experiment. Dobutamine elicited its effects during the active phase of the loop and the passive re-lengthening of the muscle (Fig. 4b). An increase in the peak force was observed, however, this increase in force was not sustained throughout the whole of the second phase. During the third phase, the force during re-lengthening was lower compared to stabilisation which reduced the negative work during re-lengthening to initial length and hence net power output.

Isoprenaline (30 nM) caused a significant increase in power output of 14% (±9%) after 10 minutes of drug treatment when compared to the control (p = 0.03) (Fig. 5a). During the remainder of the experiment, the drug induced increase in muscle performance declined and reached power values comparable to the vehicle values. Isoprenaline also elicited its effects during the second and third phase of the work-loop in a similar manner to dobutamine causing an increase in peak work-loop force and a lower force during re-lengthening to initial length Fig. 5b.

---

**Figure 3.** (a) The effect of digoxin administration on the power output of the muscle (n = 6) compared to the vehicle control treatment (n = 7). All muscles underwent a 20-minute stabilisation period (shown in grey); followed by 60 minutes of either control- or drug- treatment. The power values for the control- and drug- treatment are expressed as a percentage of the average value during stabilisation. Values are presented as mean ± SEM. (n = 6–7). Two-way repeated measures ANOVA followed by independent samples t-test for each time point DMSO vehicle control vs Digoxin: *p < 0.05, **p < 0.01 and ***p < 0.001. (b) The effect of digoxin on representative work-loop shapes. The black dashed loop is from the end of the stabilisation period (20 minutes), the red loop is from the point of maximal drug response (55 minutes overall).
Negative inotropes. Verapamil (1 µM) caused a significant (p = 0.05) decrease in the power output of the muscle after 40 minutes of drug treatment (60 minutes overall) when compared to the time-matched control (Fig. 6a). The largest difference in power output was observed 45 minutes into the drug treatment, the power output was 17% (± 9%) lower compared to the time-matched vehicle control treatment. A significant reduction in power output was sustained for the remainder of the time course. Verapamil elicited its effects during the second and third phase of the work-loop causing a reduction in the force produced by the muscle during both phases including a reduction in the peak force when compared to stabilisation (Fig. 6b).

Flecainide 3 µM caused a significant (p = 0.009) decrease of 16% (± 6%) in the power output after 40 minutes of drug treatment when compared to the control (Fig. 7a). This decrease in power output remained significant until the end of the drug treatment (p < 0.05). Figure 7b shows that flecainide caused a reduction in the force produced by the muscle throughout all three phases of the work-loop including a reduction in the peak force at the beginning of phase 2.

Atenolol 20 µM caused a significant (p = 0.046) reduction of 13% (± 7%) in the power output of the muscle after 45 minutes of drug treatment (Fig. 8a). Figure 8b shows that atenolol caused a reduction in the force produced by the muscle during the second and third phase of the work-loop.

Discussion

The heart is a dynamic organ and cardiac contraction is made possible by a complex interplay between the electrical and structural changes that directly result in the specific function of the heart[1]. The process is complex and specific meaning a small change in the structural, electrical or other changes can result in significant changes in the performance of the heart and its function. It is therefore imperative to regard the structural biomechanics of the heart when designing in vitro contractility assays.

In this study, six known inotropes have been used to assess the suitability of the cardiac work-loop technique for identification of inotropes. Each of the compounds tested caused a significant change in the power output of the muscle when compared to the appropriate vehicle control. Digoxin, dobutamine and isoprenaline caused significant increases in the power output (Fig. 9) of the muscle and were therefore successfully classified as positive inotropes. Verapamil, flecainide and atenolol caused a significant decrease in the power output (Fig. 9) and were successfully classified as negative inotropes. The compounds used in this study were chosen because their activity in vivo and in vitro has been well documented within the literature. Table 2 details how the concentrations used in this study compare to other in vitro studies and human in vivo studies.
Positive inotropes. Work-loop data presented here shows that digoxin (1 µM) significantly increased cardiac muscle performance and caused elevated forces during muscle shortening as observed from the work-loop shape (Fig. 3). Digoxin is a cardiac glycoside and inhibits sodium-potassium ATPase (Na⁺/K⁺-ATPase)₃₂. Inhibition causes an increase in the levels of intracellular sodium, reducing the concentration gradient of sodium which in turn decreases the activity of the sodium–calcium exchanger. As a result, less calcium is transported out of the cell leading to an increase in the concentration of intracellular calcium; triggering release of further calcium from the sarcoplasmic reticulum. The dose-dependent effect of intracellular calcium on contractility is well documented₃₃,₃₄ and is in part due to higher level of calcium binding to troponin C as it is one of the main regulators of contraction in cardiac muscle₃₅. Digoxin does not affect the activation or relaxation of cardiac tissue, reflected in no effect being seen during the activation and passive re-lengthening phases of the cardiac work-loop (Fig. 3b). As detailed in Table 2, the concentration of digoxin used here was comparable to the concentration used in other in vitro contractility experiments₃₆–₃₉. Rosic et al.₃₈ reported roughly a 25% increase in left-ventricular diastolic pressure following infusion of 5 µM Digoxin in Langendorff perfused guinea pig hearts. Guo et al.₃₉ reported that 1 µM Digoxin caused a 31% increase in Ca²⁺-wave amplitude in human induced pluripotent stem cell cardiomyocytes (hiPSC-CM)₃₉.

Both dobutamine and isoprenaline are adrenoreceptor agonists; dobutamine is predominantly a β₁ and α₁ receptor agonist with weak β₂ activity; isoprenaline activates both β₁ and β₂ receptors. Activation of β₁-adrenoreceptors activates the Gₛ subunit of the adrenoceptor which initially directly activates the L-type calcium channel. Secondly, it activates adenyl cyclase to form cAMP using ATP. An increase in the level of cAMP activates cAMP dependent protein kinase (protein kinase A) which phosphorylates numerous targets including: L-type calcium channels, phospholamban and troponin I₄₀. Phosphorylation of L-type calcium channels results in a greater availability of intracellular calcium during systole which consequently increases contractility during the subsequent diastole₄₀. This effect was observed in this study as an increase in force during shortening of the muscle. Phosphorylation of phospholamban causes more rapid removal of calcium from the cytosol into the sarcoplasnic reticulum enhancing relaxation of the muscle. Finally, enhanced calcium dissociation from myofilaments during diastole due to phosphorylation of troponin I which enhances relaxation of the muscle₄₀,₄₁. Increased levels of relaxation were also observed experimentally with lower forces being recorded during passive re-lengthening of the muscle. Layland et al.₃₉ also observed an acceleration of twitch relaxation with 5 µM of
isoprenaline. Brown and Erdmann observed ~60% increase in the isometric force in cat papillary muscles when perfused with ~50 µM dobutamine this is a similar amplitude of response as observed in this study at 1 µM.

Although both isoprenaline and dobutamine elicit their effects through similar mechanisms and their effects on the shape of the work-loop are similar, the magnitude and duration of the inotropic effect was much lower with isoprenaline. This may in part be due to the concentration of isoprenaline used. A dose response study was carried out for isoprenaline 10 nM–1 µM (data not shown here); it was found that concentrations of 100 nM and above caused the muscle to contract spontaneously as a result of its chronotropic and proarrhythmic properties. Hence, in this study a concentration of 30 nM was used. The addition of a chelating agent such as EDTA or EGTA would have inhibited the oxidation of isoprenaline and may have resulted in a greater increase in power output.

Negative inotropes. Verapamil causes negative inotropy by blocking both L-type and T-type voltage-gated calcium channels. This causes a decrease in the intracellular calcium levels which reduces the probability of the opening of the intracellular ryanodine receptors. As a result, treatment with verapamil reduces both the probability of contraction and the force of contraction. Verapamil reduced the power output of the muscle during shortening and also reduced the force required to re-lengthen the muscle, it had no effect on the activation of the muscle (Fig. 6b). As shown in Table 2, the concentration used in this study is comparable to the concentration tested previously by Noguchi et al. A cumulative dose-response (1 nM–100 µM) for verapamil was carried out using guinea pig papillary muscles which underwent isometric contractions at frequency of 1 Hz. At a cumulative dose of 1 µM the developed force was ~40% compared to the control, however, the duration of each dose is unknown. In the current study the duration of drug treatment was restricted to 60 minutes meaning verapamil may not have elicited its maximal effect.

Flecainide is a Na,1.5 sodium channel blocker and an inhibitor of ryanodine receptor 2 (RyR2). Flecainide was tested using rabbit papillary muscles. Josephson et al. observed a decrease in developed force of around 20% at a concentration of 5 µg/ml (∼12 µM) and a significant decrease (p < 0.005) of around 30% at a concentration of 10 µg/ml (∼24 µM). The magnitude of the response is comparable to this study, however,
the concentrations used were significantly higher. Flecainide was tested in a cumulative concentration-response study using human trabecular bundles. 3 µM flecainide caused ~15% reduction in peak isometric force compared to vehicle. This response was not significant (p > 0.05) however the magnitude of the response is comparable to this study.

In this study, atenolol has been shown to be a negative inotrope. Atenolol is a β1-adrenergic receptor blocker; it blocks endogenous adrenaline and noradrenaline. It has been demonstrated that electrical stimulation of isolated cardiac muscle elicits a contraction accompanied by noradrenaline release. It has also been demonstrated that this adrenergic response to field stimulation can be markedly reduced by propranolol (a β1 and β2 adrenergic receptor blocker). Therefore, atenolol may also significantly reduce noradrenaline release and hence reduce contractility. Atenolol also acts as an inverse agonist on β1 and β2 adrenoceptors, blocking receptors which are constitutively active. It is hypothesised that the observed response was due to atenolol blocking endogenous adrenaline and noradrenaline and also acting as an inverse agonist. Atenolol exhibited its effects during the shortening and passive re-lengthening phases of the work-loop. Varma et al. tested atenolol at various concentrations in the right atria, left atria, right ventricles and isolated papillary muscles from the rat myocardium. They carried out isometric contractions at a frequency of 1 Hz. They found that there was no difference in contractile force when papillary muscles were treated with atenolol (10 nM–100 µM). A significant effect was measured in both the right and left atria at concentrations of above 100 nM. Kerns et al. tested atenolol using the rat Langendorff perfused heart model. Using a concentration of 25 mg/mL (~9.4 µM) atenolol significantly (p < 0.05) reduced left ventricular pressure after 60 minutes. Clinically, atenolol has been observed to cause a reduction in systolic and diastolic blood pressures of around 15% and a reduction in cardiac output of around 20% which is of similar magnitude to the reduction in power that has been observed in this study.

In the present study, the work-loop technique incorporated an electrical stimulation along with a sinusoidal length change which mimics the cardiac cycle in vivo more closely than other contractility techniques. Incorporating a physiologically relevant length change is one of the main advantages of the work-loop technique over other in vitro techniques such as isometric contraction studies. This work has successfully shown that the cardiac work-loop technique is useful in assessing the effects of inotropic agents on cardiac muscle contractility since it is sensitive to changes in force, velocity, activation rate and frequency. Further assessment of the effects of: phosphodiesterase type 3 inhibitors (e.g. pimobendan or milrinone), calcium sensitizers (e.g. levosimendan),
Na\textsuperscript{+} channel blockers (e.g. disopyramide) and those with more complex mechanisms of action (e.g. amitriptyline, quinidine) would support additional validation of the work-loop assay in the future.

In conclusion we have demonstrated that the work-loop model provides a more physiologically realistic technique for studying isolated cardiac muscle. The work-loop model enables the mechanical work of the muscle to be assessed. This is the first study in which known inotropes of various classes have been tested in the cardiac work-loop at a physiologically relevant temperature in order to assess its suitability as a contractility assay. By correctly identifying the inotropes this technique has been shown to have the potential to be used

---

**Figure 8.** (a) The effect of atenolol administration on the power output of the muscle (n = 7) compared to the control treatment. All muscles underwent a 20-minute stabilisation period (shown in grey); followed by 60 minutes of either control- or drug- treatment. The power values for the control- and drug- treatment are expressed as a percentage of the average value during stabilisation. Values are presented as mean ± SEM. (n = 7–8). Two-way repeated measures ANOVA followed by independent samples t-test for each time point KH vehicle control vs Atenolol: *p<0.05. (b) The effect of atenolol on representative work-loop shapes. The black dashed loop is from the end of the stabilisation period (20 minutes), the red loop is from the point of maximal drug response (60 minutes overall).

---

**Figure 9.** Maximal drug response for each compound when compared to appropriate vehicle control, results presented as mean ± SEM. *p = 0.046 atenolol vs KH vehicle control (60 minutes overall), #p = 0.009 flecainide vs KH vehicle control (60 minutes), £p = 0.041 verapamil vs KH control (75 minutes), @p = 0.03 isoprenaline vs KH control (30 minutes), $$$p = 0.0004 dobutamine vs 0.01% DMSO control (30 minutes), +++p = 0.001 digoxin vs 0.01% DMSO control (55 minutes).
Table 2. Comparison between the concentration of compounds used in this study and concentrations used in other in vitro studies and the estimated free concentration which is based on the measured plasma concentration.

| Compound   | Concentration used in this study (µM) | Solution concentration (µM) | Reference | Plasma concentration (ng/ml) | Estimated free concentration (µM) | Reference |
|------------|---------------------------------------|-----------------------------|-----------|-----------------------------|----------------------------------|-----------|
| Digoxin    | 1                                     | 30                          | 1         | 1.32                        | 0.002                            | 54        |
|            |                                       | 0.3, 1                      | 39        |                            |                                  |           |
|            |                                       | 5                           | 47        |                            |                                  |           |
|            |                                       | 0.03–10                      | 50        |                            |                                  |           |
| Dobutamine | 1                                     | 0.1–10                      | 1        | 200                         | 0.5                              | 58        |
| Isoproterenol | 0.03                               | 5                           | 29        | 0.5                         | 0.002                            | 56        |
| Verapamil  | 1                                     | 0.001–10                    | 14       | 40                          | 0.01                             | 57        |
| Flecainide | 3                                     | 12.24                       | 40        | 296                         | 0.4                              | 59        |
|            |                                       | 0.01–100                    | 37        |                            |                                  |           |
| Atenolol   | 20                                    | 0.01–30                     | 3        | 550                         | 0.2                              | 60        |
|            |                                       | –9.4                        | 82        |                            |                                  |           |

as a preclinical assay for contractility. This type of work-loop model has the potential to enable researchers to understand mechanical defects underlying cardiac diseases and subsequently study drug effects in various disease conditions. This is the first study in which changes in work-loop shape detailing for example the activation, shortening or passive re-lengthening have been linked to the mechanism of action of the compound and is a useful method with which to assess detailed mechanisms of drug-induced effects on cardiac muscle contractility.

Received: 12 September 2019; Accepted: 26 November 2019;
Published online: 24 March 2020

References
1. Sagawa, K., Suga, H., Shoukas, A. A. & Bakalar, K. M. End-systolic pressure/volume ratio: A new index of ventricular contractility. *Am. J. Cardiol.* **40**, 748–753 (1977).
2. Bombardini, T. Myocardial contractility in the echo lab: Molecular, cellular and pathophysiological basis. *Cardiovasc. Ultrasound* **3**, 1–22 (2005).
3. Burkoff, D., Mirsky, I. & Suga, H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. *Am. J. Physiol. Circ. Physiol.* **289**, H501–H512 (2005).
4. National Institute for Health and Care Excellence. Chronic heart failure in adults: diagnosis and management (QS9). Available at, https://www.nice.org.uk/guidance/qs9/resources/chronic-heart-failure-in-adults-pdf-5830446483. 16–18 (2019).
5. National Institute for Health and Care Excellence. Acute heart failure: diagnosis and management (CG187). Available at, https://www.nice.org.uk/guidance/cg187/resources/acute-heart-failure-diagnosis-and-management-pdf-35109817738693. (2018).
6. Nishimura, R. A. & Tajik, A. J. Quantitative hemodynamics by Doppler echocardiography: A noninvasive alternative to cardiac catheterization. *Prog. Cardiovasc. Dis.* **36**, 309–342 (1994).
7. Beigel, R., Cercek, B., Siegel, R. J. & Hamilton, M. A. Echo-Doppler hemodynamics: An important management tool for today’s heart failure care. *Circulation* **131**, 1031–1034 (2015).
8. Bell, R. M., Mocanu, M. M. & Yellon, D. M. Retrograde heart perfusion: The Langendorff technique of isolated heart perfusion. *J. Mol. Cell. Cardiol.* **50**, 940–950 (2011).
9. Varma, D. R. et al. Inverse agonist activities of β-adrenoceptor antagonists in rat myocardium. *Br. J. Pharmacol.* **127**, 895–902 (1999).
10. Brown, L. & Erdmann, E. Concentration-response curves of positive inotropic agents before and after ouabain pretreatment. *Am. J. Physiol. Circ. Physiol.* **269**, H501–H512 (2005).
11. James, R. S., Young, I. S., Cox, V. M., Goldspink, D. F. & Altringham, J. D. Isometric and isotonic muscle properties as determinants of work loop power output. *Pflugers Arch. Eur. J. Physiol.* **432**, 767–774 (1996).
12. Gharanei, M., Hussain, A., James, R. S., Janneh, O. & Maddock, H. Investigation into the cardiotoxic effects of doxorubicin on contractile function and the protection afforded by cyclosporin A using the work-loop assay. *Toxicol. Vitr.* **28**, 722–731 (2014).
13. Caiozzo, V. J. Plasticity of skeletal muscle phenotype: mechanical consequences. *Muscle Nerve* **26**, 740–768 (2002).
14. Josephson, R. Contraction dynamics and power output of skeletal muscle. *Annu. Rev. Physiol.* **55**, 527–546 (1993).
15. Batista, L., Bastogne, T., Delaunois, A., Valentin, J.-P. & Atienzar, F. A novel statistical signal processing method to estimate effects of compounds on contractility of cardiomyocytes using impedance assays. *Biomed. Signal Process. Control* **45**, 202–212 (2018).
16. Scott, C. W. et al. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. *Toxicol. Sci.* **142**, 331–338 (2014).
17. Peters, M. F., Lamore, S. D., Guo, L., Scott, C. W. & Kolaja, K. L. Human Stem Cell-Derived Cardiomyocytes in Cellular Impedance Assays: Brining Cardiototoxicity Screening to the Front Line. *Cardiовasc. Toxicol.* **15**, 127–139 (2015).
18. Butler, L. et al. Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment. *Toxicol. Sci.* **145**, 396–406 (2015).
19. Delhaas, T., Arts, T., Prinzen, F. W. & Reneman, R. S. Relation between regional electrical activation time and subepicardial fiber strain in the canine left ventricle. *Pflugers Arch. Eur. J. Physiol.* **423**, 78–87 (1993).
20. Semafuko, W. & Bowie, W. Papillary muscle dynamics: in situ function and responses of the papillary muscle. *Am. J. Physiol.* **228**, 1800–1807 (1975).
21. Mellors, L. J. & Barclay, C. J. The energetics of rat papillary muscles undergoing realistic strain patterns. *J Exp Biol* **204**, 3765–3777 (2001).
22. Josephson, R. K. Mechanical power output from striated muscle during cyclic contraction. *J. Exp. Biol.* **114**, 493–512 (1985).
23. Tallis, J., Hill, C., James, R. S., Cox, V. M. & Seebacher, F. The effect of obesity on the contractile performance of isolated mouse soleus, EDL, and diaphragm muscles. *J. Appl. Physiol.* **122**, 170–181 (2017).
53. Heel, R. C., Brogden, R. N., Speight, T. M. & Avery, G. S. Atenolol.

57. Eichelbaum, M., Birkel, P., Grube, E., Gütgemann, U. & Somogyi, A. Effects of verapamil on P-R-intervals in relation to verapamil

43. Catterall, W. A. Voltage-gated calcium channels.

42. Bergson, P., Lipkind, G., Lee, S. P., Duban, M.-E. & Hanck, D. A. Verapamil Block of T-Type Calcium Channels.

45. Mehra, D., Imtiaz, M. S., van Helden, D. F., Knollmann, B. C. & Laver, D. R. Multiple modes of ryanodine receptor 2 inhibition by

48. Blinks, J. R. & Plummer, E. F. Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart

46. Josephson, M. A., Ikeda, N. & Singh, B. N. Effects of flecainide on ventricular function: Clinical and experimental correlations.

37. Lüllman, H. & Ravens, U. The time courses of the changes in contractile force and in transmembrane potentials induced by cardiac

36. Aylin, A. M.

38. Rosic, M. A., Segal, M. B., Collis, C. S., Egleton, R. & Andjelkovic, I. Z. Propranolol inhibits cimetidine potentiation of digoxin effects

34. Eisner, D. A., Caldwell, J. L., Kistamás, K. & Trafford, A. W. Calcium and Excitation-Contraction Coupling in the Heart.

33. Bers, D. M. Cardiac excitation-contraction coupling.

32. Akera, T. & Brody, T. M. The Role of Na,K-ATPase in the Inotropic Action of Digitalis.

27. Layland, J. & Kentish, J. C. Myofilament-based relaxant effect of isoprenaline revealed during work-loop contractions in rat cardiac

28. Layland, J. & Kentish, J. C. Effects of

30. Vinnakota, K. C. & Bassingthwaighte, J. B. Myocardial density and composition: A basis for calculating intracellular metabolite concentrations. Am. J. Physiol. - Hear. Circ. Physiol. 286, H1742–H1749 (2004).

31. Spinale, F. G. Assessment of cardiac function-Basic principles and approaches. Circ. Res. 5, 1911–1946 (2015).

32. Akerà, T. & Brody, T. M. The Role of Na,K-ATPase in the Inotropic Action of Digitoxin. PharmacoL Rev. 29, 187–221 (1978).

33. May, M. D. Cardiac excitation-contraction coupling. Nature 415, 198–205 (2002).

34. Eisner, D. A., Caldwell, J. L., Kistamås, K. & Trafford, A. W. Calcium and Excitation-Contraction Coupling in the Heart. Circ. Res. 121, 181–195 (2017).

35. Parkes, M. S. & Solaro, R. J. Biology of the troponin complex in cardiac myocytes. Prog. Cardiovasc. Dis. 47, 159–176 (2004).

36. Aylin, A. M. et al. Interactions between Verapamil and Diginox in Langendorff-Perfused Rat Hearts: The Role of Inhibition of P-glycoprotein in the Heart. Basic Clin. Pharmacol. Toxicol. 107, 847–852 (2010).

37. Lüllman, H. & Ravens, U. The time courses of the changes in contractile force and in transmembrane potentials induced by cardiac
glycodies in guinea-pig papillary muscle. Br. J. Pharmacol. 49, 377–390 (1973).

38. Kosic, M. A., Segal, M. B., Collis, C. S., Egleton, R. & Andjelkovic, I. Z. Propranolol inhibits cimetidine potentiation of digoxin effects

39. Guo, L. et al. The electrophysiological effects of cardiac glycodies in human iPSC-derived cardiomyocytes and in guinea pig isolated

40. Takimoto, E. et al. Frequency- and Afterload-Dependent Cardiac Modulation In Vivo by Troponin I With Constitutively Active Protein Kinase A Phosphorylation Sites. Circ. Res. 94, 496–504 (2004).

41. Zhang, R., Zhao, J., Mandreveno, A. & Potter, J. D. Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation. Circ. Res. 76, 1028–35 (1995).

42. Bergson, P., Lipkind, G., Lee, S. P., Duban, M.-E. & Hanck, D. A. Verapamil Block of T-Type Calcium Channels. Mol. Pharmacol. 79, 411–419 (2010).

43. Catterall, W. A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol. 3, 1–5 (2011).

44. Noguchi, K., Takahashi, K. & Higuchi, S. In vitro Negative Chronotropic and Inotropic Effects of a Novel Dihydropyridine Derivative, CD-832, in the Guinea-pig. Comparison with Calcium-channel Antagonists. J. Pharm. Pharmacol. 50, 329–334 (1998).

45. Mehra, D., Imitiaz, M. S., van Helden, D. F., Knollmann, B. C. & Laver, D. R. Multiple modes of rydanoide receptor 2 inhibition by

46. Josephson, M. A., Ikeda, N. & Singh, B. N. Effects of flecainide on ventricular function: Clinical and experimental correlations. Am. J. Cardiol. 53, (1984).

47. Lynch, J. J., Regan, C. P., Beatich, G. N., Gleim, G. W. & Morabito, C. J. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vrenalakin and flecainide in human isolated vascular and cardiac tissues. J. Cardiovasc. Pharmacol. 61, 226–232 (2013).

48. Blanks, J. R. & Plummer, E. F. Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart

49. Olson, R. D., Vestal, R. E., Mendenhall, W. A. & Mudumbai, R. V. Quantification of the voltage-response relationship between punctate and field electrical stimulation and the function of isolated rat atria and papillary muscles. J. Pharmacol. Toxicol. Methods 34, 225–230 (1995).

50. Tank, A. W. & Wong, D. L. Peripheral and central effects of circulating catecholamines. Compr. Physiol. 5, 1–15 (2015).

51. Seifert, R. & Wenzel-Seifert, K. Constituitive activity of G-proteins-coupled receptors: Cause of disease and common property of

52. Kerns, W., Ransom, M., Tomaszewski, C., Kline, J. & Raymond, R. The effects of extracellular ions on βblocker cardiotoxicity. Toxicol. Appl. Pharmacol. 137, 1–7 (1996).

53. Heel, R. C., Brogren, R. N., Speight, T. M. & Avery, G. S. Atenolol. Drugs 17, 425–460 (1979).

54. Schwartz, J. I. et al. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br. J. Clin. Pharmacol. 66, 811–8 (2008).

55. Landsberg, J. S., Parker, J. D., Gauthier, D. F. & Colucci, W. S. Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation 84, 1608–1614 (1991).

56. Conolly, M. E. et al. Metabolism of isoproterenol in dog and man. Br. J. Pharmacol. 46, 458–472 (1972).

57. Eichelbaum, M., Birkel, P., Grube, E., Gütgemann, U. & Somogyi, A. Effects of verapamil on P-R-intervals in relation to verapamil

58. Kihara, Y., Inoko, M., Hatakeyama, N., Monose, Y. & Sasyamay, S. Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. J. Cardiovasc. Pharmacol. 27, 42–51 (1996).

59. Holtzman, J. L. et al. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and

60. Lewis, R. et al. Timolol and atenolol: relationships between oxidation phenotypes, pharmacokinetics and pharmadynamics. Br. J. Clin. Pharmacol. 19, 329–333 (1985).

Acknowledgements

We would like to thank the Centre for Sport, Exercise and Life Sciences at Coventry University for funding this study and a special thanks to Adam Linekar, Oana Blair and Matthew Bonner for your advice and support during this study.

Author contributions

S.F. conducted the experiments, analysed data and wrote the manuscript H.M. designed the study and reviewed the manuscript R.W. reviewed the manuscript R.J. designed the study and reviewed the manuscript M.G. designed and supervised the study and reviewed the manuscript.
Competing interests
Helen Maddock, Rob Wallis and Mayel Gharanei were also (in part) employees of InoCardia Ltd. This study was part of a studentship that was co-funded by InoCardia Ltd. No other conflict of interest were declared.

Additional information
Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020